HIV-1 tropism, disease progression, and clinical management

Journal of Infectious Diseases

Volumn 198, Issue 8, 2008, Pages 1095-1097

  Burger, Harold ^a,b   Hoover, Donald ^c  

^a WADSWORTH CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CELL LOSS; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DISEASE COURSE; EDITORIAL; HETERODUPLEX ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; VIRUS LOAD; VIRUS STRAIN;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 54749087844     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/591624     Document Type: Editorial

References (27)

1. + cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-8.
2. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
3. Ray N, Doms RW. HIV-1 coreceptors and their inhibitors. Curr Topics Microbiol Immunol 2006; 303:97-120.
4. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997; 71:7478-87.
5. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73:10489-502.
6. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3:1259-65.
7. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-8.
8. + T cell decline. Proc Natl Acad Sci U S A 2000; 97:1269-74.
9. Kreisberg JF, Kwa D, Schramm B, et al. Cytopathicity of human immuno-deficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J Virol 2001; 75:8842-7.
10. Jekle A, Keppler OT, De Clercq E, et al. In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 2003; 77:5846-54.
11. Brumme ZL, Dong W, Yip B, et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004; 18:F1-9.
12. Proveda E, Briz V, de Mendoza C, et al. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 2007; 79:1040-6.
13. Weiser B, Philpott S, Klimkait T, et al. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008; 22:469-79.
14. Daar ES, Kesler KL, Petropoulos CJ, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643-9.
15. Waters L, Mandalia S, Randell P, et al. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46:1617-23.
16. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
17. 6/l. AIDS 2002; 16:1371-81.
18. Sterling TR, Chaisson RE, Keruly J, et al. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 2003; 188:1659-65.
19. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-61.
20. Holmberg SD, Palella FJ Jr, Lichtenstein KA, et al. The case for earlier treatment of HIV infection. Clin Infect Dis 2004; 39:1699-704.
21. Phillips AN, Lepri AC, Lampe F, et al. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003; 17:1863-9.
22. Hughes MD, Ribaudo HR. The search for data on when to start treatment for HIV infection. J Infect Dis 2008; 197:1084-6.
23. Hirsch MS. Initiating therapy: when to start, what to use. J Infect Dis 2008; 197:S252-60.
24. Shepherd JC, Jacobson LP, Qiao W, et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the Multicenter AIDS Cohort Study. J Infect Dis 2008; 198:1104-12 (in this issue).
25. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor. AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591-5.
26. Gange SJ, Munoz A, Chmiel JS, et al. Identification of inflection in T-cell counts among HIV-1 infected individuals and relationship with progression to clinical AIDS. Proc Natl Acad Sci U S A 1998; 95:10848-53.
27. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-72.